The latest 54 drug approvals! 18 consistency applications! O nitrogen flat, right metomeding...

Today, the State Drug Administration issued "January 21, 2021 drug approval documents to be received information", information shows that a total of 54 approvals were approved, including Qilu Pharmaceutical's O nitrogen flat mouth solution film, Hengrui Pharmaceutical's hydrochloric acid right metomide sodium chloride injection and Jiangsu Enhua Pharmaceuticals, Yichang Renfu Pharmaceuticals and other 5 enterprises declared hydrochloric acid right metomide injections and other large varieties.
is also noteworthy that 18 of the 54 approvals were approved for consistency of generic drug varieties, with multiple approvals for consistency.
the following for Sina pharmaceutical finishing of several of the key varieties: the domestic second O nitrogen flat mouth dissolved membrane listed O nitrogen plain research from Lilly, the commodity name "Repule."
first launched in China in 1998 to treat schizophrenia, moderate to severe mania and bipolar disorder.
China's urban public hospitals, county-level public hospitals, urban community centers and township hospitals (China's public medical institutions) terminal sales of more than 4 billion yuan in 2019, according to Mina network data.
the current domestic market of O nitrogen flat products are O nitrogen flat tablets, O nitrogen flat mouth collapse and O nitrogen flat mouth dissolved film.
November 24, 2020, Jiangsu Haussen Pharmaceuticals O nitrogen flat mouth dissolved membrane was approved as the first domestic, and now Qilu Pharmaceutical has become the second domestic.
it is learned that, before, Qilu's O nitrogen flat tablets and mouth collapse tablets have passed the consistent evaluation, its O nitrogen flat tablets in the "4 plus 7" band purchase expansion with 2.48 yuan / piece price finalist, its O nitrogen flat flat tablets with 6.3 yuan / piece price into the third batch of collection catalog.
approval of the oral instant film will be another heavyweight product in the field of the central nervous system in its layout.
that oral membrane agent is an improved new drug, in recent years has been widely concerned.
5 hydrochloric acid right metomide injection evaluation this time a total of Jiangsu Enhua Pharmaceuticals, Yichang Renfu Pharmaceuticals, Hunan Colum, Sichuan Guorui Pharmaceuticals, Chengdu Bett Pharmaceuticals 5 pharmaceutical companies of hydrochloric acid right metomide injections through a consistent evaluation.
Hydrochloric acid right metomidine injection developed jointly by Oricon Pharma and Abbott, with central anti-crosssal and anti-anxiety effects, can produce a calming effect similar to natural sleep, clinically mainly used for tracheal intitutation ventilator treatment of patients sedation, perioperative anesthesia combined medication and invasive examination or treatment of sedation.
was first approved by the FDA in December 1999 under the name Precedex ®.
follow-up in the European Union, Japan and other countries and regions listed for sale.
according to the Minenet database, sales of hydrochloric acid right metomymethylin injections in urban sample public hospitals nationwide in 2019 amounted to 2,872 million yuan.
At present, the domestic hydrochloric acid right metomide injection has Hengrui Pharmaceuticals, Renfu Pharmaceuticals, Chenxin Pharmaceuticals, Enhua Pharmaceuticals and other enterprises have been approved for listing;
can see that the competitive situation of this product is getting stronger! Hydrochloric acid right metomide sodium chloride injection listed, the first imitation of this approved variety, there is also a worthy of attention, that is, Hengrui medicine's hydrochloric acid right metomide sodium chloride injection.
it is known that the current market of hydrochloric acid right metomide products mainly include the above mentioned hydrochloric acid right metomide injection and this hydrochloric acid right metomide sodium chloride infusion / injection type.
Sodium chloride injection is a relatively selective alpha2-epinephrine-subject agonist that is suitable for sedation in patients who are not intestored before or during surgery or other operations.
sodium chloride injection for hydrochloric acid, was first approved in the United States in 2013 under the name Precedex.
according to insight data, before the domestic hydrochloric acid right metomide sodium chloride injection has not been approved for the market, Hengrui pharmaceutical successfully approved to become the first imitation of the variety.
In 2019, Hengrui Pharmaceuticals' hydrochloric acid right metomide sodium chloride infusion was provisionally approved by the FDA (provisional approval refers to the FDA has completed all the review process for the drug, but there are cases where the relevant patent has not expired).
June 2020, the application for a short new drug for the sodium chloride injection of right metomide hydrochloride was formally approved by the FDA.
2019, global sales of sodium chloride injections were about $175 million, and U.S. sales were about $130 million, according to the IMS database.
addition, Chengdu Bett Pharmaceuticals, Yangzijiang Pharmaceutical Group and other enterprises submitted the right metomide sodium chloride injection application, Hunan Colum Pharmaceuticals submitted a clinical application.
, Augata Pharmaceutical Innovation Drug - Meathan Potassium Tablets January 19, Takeda Pharmaceuticals Class 1 new drug Meathan Potassium Tablets listed application was approved by the State Drug Administration for the treatment of primary hypertension.
methadan potassium is a hemangiotensin II blocker developed by Takeda, an oral pre-drug that can be rapidly metabolized by esterase into the active ingredient Azishatan during the absorption process.
the latter can selectively block angiosculose II by binding to many tissues such as angiosmosis muscles and AT1 receptors in the adrenal glands to block angioconstrication and aldosterone secretion.
, its effect is not related to angiosin II synthesis pathway.
Azishatan's affinity for AT1 receptors is more than 10,000 times that of AT2 receptors.
first approved by the FDA for listing in 2011.
is currently listed in the United States, Canada, France, the United Kingdom and other countries around the world.
2019, PotashCorp generated 76.7 billion yen in revenue for Takeda, or about 4.8 billion yuan, according to the Medical Cube database.
in addition to the above several varieties, the approved varieties, Zhengda Qing injection with boron zomi, Guangzhou Langsan Pharmaceuticals Tadara non-tablets and other varieties have also received many attention.
: Medical Rubik's Cube: Takeda Class 1 New Drug "Measatan Potassium Tablets" to Be Approved for Market